MODERNA BIOTECH UK LIMITED

• ◆

  Outstanding charges registered

  One or more mortgages or charges remain undischarged on the Companies House register.

1. MODERNA BIOTECH UK LIMITED 2020-06-17 → present
2. MODERNATX, LTD. 2019-05-10 → 2020-06-17

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Due to the nature of the Company, as an intermediate holding and financing company, the Company is dependent on support from the Group. As a result, a letter of support has been obtained in which the ultimate parent Moderna, Inc., has stated in writing that it will provide financial support until 31 December 2026 to allow the Company to meet its financial commitments and pay liabilities as they fall due.”

Group structure

1. MODERNA BIOTECH UK LIMITED · parent
   1. Moderna Belgium SRL 100% · Belgium · Pharmaceutical and Medicine Manufacturing
   2. Moderna Biopharma Canada Corporation 100% · Canada · Development, procurement, and distribution of Moderna's COVID-19 vaccine
   3. Moderna Manufacturing Canada Corp. 100% · Canada · Construction of assets to manufacture basic pharmaceutical products
   4. Moderna Switzerland GmbH 100% · Switzerland · Development, importation, marketing, manufacture and distribution of pharmaceuticals
   5. SAS Moderna France 100% · France · Development, importation, manufacture, marketing, advertising, distribution and sale of vaccines and drugs
   6. Moderna Norway AS 100% · Norway · Conduct business with medicines, including import, promotion, marketing and distribution of health and pharmaceutical products
   7. Moderna Italy SRL 100% · Italy · Research and experimental developmental in the field of biotechnology
   8. Moderna Sweden AB 100% · Sweden · Development, import, export, marketing and distribution of pharmaceuticals
   9. Moderna Biotech Spain, S.L.U. 100% · Spain · Development, import, manufacturing, marketing and distribution of medicines
   10. Moderna Biotech Ireland Limited 100% · Ireland · Dormant entity
   11. Moderna Germany GmbH 100% · Germany · Development, import, marketing, manufacture and distribution of drags, vaccine and medicines
   12. Moderna Netherlands B.V. 100% · Netherlands · Development, import, marketing, manufacture and distribution of drags, vaccine and medicines
   13. Moderna Japan Co. Ltd 100% · Japan · Development, import, export, manufacturing, marketing and distribution of drugs, vaccines and medicines
   14. Moderna Korea Limited 100% · South Korea · Research & development of medicines; Import, marketing and distribution of medicines
   15. Moderna Malaysia Sdn. Bhd. 100% · Malaysia · Dormant entity
   16. Moderna Taiwan Co., Ltd 100% · Taiwan · Wholesale of pharmaceutical products; International trade; Biotechnology services; Research and development services
   17. Moderna Biotech Singapore Pte. Ltd 100% · Singapore · Wholesale of medicinal and pharmaceutical products; Importation, marketing and distribution of messenger-RNA medicines and related activities
   18. Moderna Hong Kong Limited 100% · Hong Kong · Importation and promotion of medicines and other types of medical products to medical professionals
   19. Moderna Biotech Distributor UK Ltd 100% · United Kingdom · Other professional, scientific and technical activities
   20. Moderna Arabia Biotech LLC 100% · Saudi Arabia · Research and development on biotechnology
   21. Moderna Poland Sp. z o.o. 99% · Poland · Other business and management consulting services
   22. Moderna Biotech Manufacturing UK Ltd 100% · United Kingdom · Construction of assets to manufacture basic pharmaceutical products
   23. Moderna Biotech Philippines Inc. 100% · Philippines · Import, export, manufacture, marketing and wholesale distribution of drugs, vaccines
   24. Moderna (China) Investment Co., Ltd. 100% · China · Engaging in investment activities with self-owned funds, investment management, enterprise management consulting, technical services, technology development, etc.
   25. Moderna Denmark ApS 100% · Denmark · Conduct of business with pharmaceuticals
   26. Moderna Austria GmbH 100% · Austria · Dormant entity
   27. Moderna Enzymatics Co., Ltd 100% · Japan · Development, import, export, manufacturing, marketing and distribution of drugs, vaccines and medicines
   28. Moderna Portugal, Unipessoal, Lda 100% · Portugal · Development, import, export, marketing, manufacture and distribution of drugs, vaccines and medicines

Significant events

• “On 28 June 2024, the company purchased Moderna Enzymatics Co., Ltd via capital contribution of $69,124,612 (translated to £54,121,995).”
• “Amounts written off investments increased significantly during the year, resulting from an impairment review undertaken by the Company.”
• “During the financial year, the Company's rental office at Harwell Campus (Quad 2) was relocated from Moderna Biotech UK Limited to Moderna Biotech Manufacturing UK Limited.”
• “The subsidiaries Moderna Biotech Philippines Inc., Moderna Arabia Biotech LLC, and Moderna Malaysia Sdn. Bhd. are in dissolution process in 2025 period.”
• “Moderna Denmark ApS, Moderna Austria GmbH, Moderna Biotech Ireland Limited, and Moderna Belgium SRL have been officially dissolved.”
• “On 1 April 2023, a Business Transfer Agreement was executed between the Company and its subsidiary, Moderna Biotech Distributor UK Ltd, transferring all activities related to research and development, marketing, or commercialization of pharmaceutical products, assets, contractual relationships, and employees to Moderna Biotech Distributor UK Ltd for £1.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -87.4%

  £4,795,782 → £605,023

• Cash

  —

  Not reported

• Net assets

  —

  Not reported

• Employees

  —

  Not reported

• Operating profit

  -230.4%

  £213,790 → -£278,778

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers